TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors

Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed malignant ovarian germ cell tumor patients after surgery.

Trial Details

NCT ID
NCT02429687
Phase
PHASE3
Sponsor
Beihua Kong
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Paclitaxel
  • Carboplatin
  • Bleomycin
  • Etoposide
  • Cisplatin
Locations (sample)
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Age≤65 years; female, Chinese women;
  • Histologically confirmed ovarian stromal tumor, including the following cell types:
  • Granulosa cell tumor
  • Granulosa cell-theca cell tumor

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →